Login / Signup

Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.

Enriqueta Vallejo-YagüeStefan WeilerRaphael MicheroliAndrea Michelle Burden
Published in: Drug safety (2021)
This study supports the current recommendation for cautious use of tofacitinib in patients with high thromboembolic risk. Moreover, with a similar patient profile and elevated reporting for baricitinib, a potential class effect of JAK inhibitors cannot be ruled out.
Keyphrases
  • rheumatoid arthritis
  • adverse drug
  • atrial fibrillation
  • ulcerative colitis
  • case report
  • emergency department
  • human health
  • drug induced